Latest News-EVEREST MEDICINES Mediaroom_Page

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023

SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2024-03-28 07:01 2979

Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2024-03-20 09:16 1478

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Compa...

2024-03-18 09:00 1679

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2024-03-12 09:28 2525

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau

-- Macau is on course to become the first of Everest's Asian territories to get etrasimod approval ...

2024-03-11 09:00 2310

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-03-06 08:59 1701

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (H...

2024-02-27 07:14 1222

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in pati...

2024-02-22 08:59 1543

Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine

--Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composi...

2024-02-21 09:00 2826

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, ...

2024-02-19 08:20 1540

Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million

SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-01-22 07:50 3075

Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline

SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-12-21 10:30 6573

Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China

-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in act...

2023-12-04 08:58 3745

Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis

--Clinically meaningful and statistically significant results demonstrated for primary endpoint and...

2023-12-01 07:33 1804

Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea

SHANGHAI, Nov. 30, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-11-30 07:25 2958

Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks ...

2023-11-24 12:54 3463

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company...

2023-10-27 13:45 1733

Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2023-10-27 08:22 1825

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its l...

2023-10-16 07:48 942

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

SHANGHAI, Oct. 5, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company...

2023-10-05 07:33 1747